Table 2.
Clinical outcomes of the patients treated with Y-90 SIRT.
| Results | Value |
|---|---|
| Pre-treatment evaluation | |
| Lung shunting (%) | 5.20 (1.32–17.70) |
| Treatment procedure | |
| Length of stay (days) | 2 (1–8) |
| Radioactivity dose (GBq) | 1.76 (0.36–4.90) |
| Technique, n (%) | |
| Unilobar | 17 (32.7) |
| Sequential bilobar | 3 (5.8) |
| Whole liver | 22 (42.3) |
| Unilobar with extrahepatic | 7 (13.5) |
| Whole liver with extrahepatic | 3 (5.8) |
| Duration of protocol | |
| Diagnosis to treatment (months) | 3.6 (0.8–53.5) |
| Pretreatment evaluation to treatment (months) | 0.5 (0.3–1.1) |
| Objective response by mRECIST, n (%) | |
| Complete response | 1 (2) |
| Partial response | 17 (33) |
| Stable disease | 10 (19) |
| Progressive disease | 24 (46) |
| Further treatment after first Y-90 SIRT, n (%)a | |
| None | 24 (46.2) |
| Repeated Y-90 SIRT | 9 (17.4) |
| TACE ± others | 10 (19.2) |
| Targeted therapy only | 5 (9.6) |
| Resection | 2 (3.8) |
| Other modalities | 2 (3.8) |
| Outcomes at the end of study, n (%) | |
| Tumor related deaths | 19 (36) |
| Liver decompensation related deaths | 16 (31) |
| Non-tumor related deaths | 5 (10) |
| Lost to follow up | 4 (8) |
| Alive | 8 (15) |
Data were expressed as median (range) or n (%).
Abbreviations: GBq, gigabecquerel; TACE, transarterial chemoembolization; Y-90 SIRT, yttrium-90 selective internal radiation therapy.
a
Some patients received more than one treatment modalities.